Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Vibostolimab/Pembrolizumab · MK-7684A

Monoclonal antibody · Immune activation, directed at VISTA (VSIR) and PD-1 (PDCD1) · developed by Merck &

Phase 1/2 Most advanced trial (none active)

MRK Developer

1 Registered trials

What is Vibostolimab/Pembrolizumab?

Vibostolimab/pembrolizumab is a bispecific antibody combining a VISTA antagonist with a PD-1 antagonist. It is studied in renal cell carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: MK-7684A
Drug type: Monoclonal antibody
Targets: VISTA (VSIR), PD-1 (PDCD1)
Mechanism: Immune activation, directed at VISTA (VSIR) and PD-1 (PDCD1)
Pathways: immune_activation
Therapy area: Oncology
Developer: Merck & Co. (MRK)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04626479	Phase 1/2	Carcinoma, Renal Cell	Completed	MRK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Carcinoma, Renal Cell

Other drugs acting on VSIR / PDCD1

Berahyaluronidase Alfa and Pembrolizumab FDA approved Nivolumab FDA approved Pembrolizumab FDA approved Toripalimab FDA approved Atigotatug/Nivolumab Phase 1 Balstilimab Phase 2/3 BPT567 Phase 1 Budigalimab Phase 2/3 Cadonilimab Early Phase 1 CDX-585 Phase 1 Cenopodlin Phase 1 CTX-8371 Phase 1

More from Merck &

BCG Live FDA approved Belzutifan FDA approved Berahyaluronidase Alfa FDA approved Berahyaluronidase Alfa and Pembrolizumab FDA approved Enlicitide FDA approved Ensifentrine FDA approved Letermovir FDA approved Pembrolizumab FDA approved Probenecid FDA approved Alimatravir Phase 2 Bomedemstat Phase 2/3 Calderasib Phase 3

Sources

ClinicalTrials.gov NCT04626479

Updated Oct 3, 2026. Something wrong or missing? Report it on the MRK page.

Follow MRK, the company behind Vibostolimab/Pembrolizumab

See MRK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MRK catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z